Last reviewed · How we verify
Part C: AZD8233
At a glance
| Generic name | Part C: AZD8233 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AZD8233 in Participants With Dyslipidemia. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part C: AZD8233 CI brief — competitive landscape report
- Part C: AZD8233 updates RSS · CI watch RSS
- AstraZeneca portfolio CI